Mahtani, Reshma L. http://orcid.org/0000-0002-7711-8627
Belani, Rajesh
Crawford, Jeffrey
Dale, David
DeCosta, Lucy
Gawade, Prasad L.
Huynh, Chanh
Lawrence, Tatiana
Lewis, Sandra
MacLaughlin, William W.
Narang, Mohit
Rifkin, Robert
Funding for this research was provided by:
amgen inc
Article History
Received: 2 July 2021
Accepted: 29 March 2022
First Online: 14 April 2022
Declarations
:
: Approval was obtained from the Institutional Review Boards for various centers involved in the study. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: Written informed consent was obtained from all participants included in the study.
: Not applicable.
: Reshma L. Mahtani reports consulting fees from Biotheranostics, Amgen, Agendia, Eisai, Immunomedics, Genentech, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, AstraZeneca, Daiichi, and participation on an advisory board for AstraZeneca, Amgen, Agendia, Biotheranostics, Eisai, Immunomedics, Lilly, Novartis, Merck, Pfizer, Puma, Sanofi, Seagen, and Daiichi; Rajesh Belani reports employment with Poseida Therapeutics and stock/stock options in Amgen; Jeffrey Crawford reports consulting fees from GlaxoSmithKline, G1 Therapeutics, Merck, Pfizer, Spectrum, and participation on a data safety monitoring board or advisory board for Beyond Spring, G1 Therapeutics, Merrimack, Mylan and Roche; David Dale reports consulting fees from Amgen, and contracted research support from Amgen; Lucy DeCosta reports employment with Amgen Inc.; Prasad L. Gawade reports employment and stockholding with Amgen Inc.; Chanh Huynh has no disclosures to report; Tatiana Lawrence reports employment and stockholding with Amgen Inc.; Sandra Lewis reports employment and stockholding with Amgen Inc.; William W. MacLaughlin and Mohit Narang have no disclosures to report; Robert Rifkin reports participation in advisory boards for Amgen, BMS (Celgene), Coherus, Fresenius-Kabi, GSK, Janssen, and Pfizer.